chrisvoncsefalvay/vaers-outcomes huggingface dataset:
coud not see straight; could not focus; exhausted; dry scratchy chest; back pain; sinus pain; felt like she would pass out; difficulty yawning and swallowing; trouble walking; chest pain; feeling terrible; difficulty breathing/difficulty yawning; chills; This case was reported by a consumer via call center representative and described the occurrence of chest pain in a 58-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Concomitant products included Flu Seasonal QIV Dresden (Influenza vaccine Quadrivalent 2020-2021 season).   On 12th February 2020, the patient received the 1st dose of Shingrix (intramuscular). In February 2020, less than a day after receiving Shingrix and less than a month after receiving Influenza vaccine Quadrivalent 2020-2021 season, the patient experienced chills. In April 2020, the patient experienced difficulty breathing. On an unknown date, the patient experienced chest pain, feels awful, visual impairment, concentration impaired, exhaustion, chest abnormal feeling of, back pain, sinus pain, felt faint, swallowing difficult and walking difficulty. On an unknown date, the outcome of the chest pain, feels awful, visual impairment, exhaustion, chest abnormal feeling of, difficulty breathing, back pain and sinus pain were not recovered/not resolved and the outcome of the chills was recovered/resolved and the outcome of the concentration impaired was recovering/resolving and the outcome of the felt faint, swallowing difficult and walking difficulty were unknown.   It was unknown if the reporter considered the chest pain, feels awful, chills, visual impairment, concentration impaired, exhaustion, chest abnormal feeling of, difficulty breathing, back pain, sinus pain, felt faint, swallowing difficult and walking difficulty to be related to Shingrix.  Additional case details were reported as follows: The patient received 1st dose of Shingrix and experienced chills the first night.  She then developed the other events chest pain, feeling terrible, dry scratchy chest, back pain and sinus pain. One month later, she felt like she would pass out, could not see straight, could not focus and was exhausted.  The patient's primary care physician assistant informed her that her reaction was not typical for a Shingrix vaccination. In April, she had difficulty breathing. She had been tested 3 times for COVID and the results were all negative. Her oxygen levels were high but she has difficulty yawning and swallowing. She took an immune system test and the results were borderline.  She used to be a hiker, but now had trouble walking down the road. The patient received her flu shot 2 weeks prior with no ill effects The reporter consent to follow up.
On June 4, 2008 in our immunization clinic, six children received their second dose of VARICELLA. We are assuming one of them received a ZOSTAVAX instead of VARIVAX due to the count at the end of the day. All parents of the children were reached by 06/11/2008. None of the children had any adverse reactions, even a local one at the site of the VARIVAX. Since we are not positive that one of these children received a ZOSTAVAX, we are only giving you the names and birthdays of these children as instructed by the representative of the states Immunization Program. If you need more information, please contact me. I called CDC on 6/11/08. In response to this situation, there was no specific answer in the literature, but the "expert" that was consulted stated that the dose of ZOSTAVAX, if given, should be "counted".
Information has been received from a licensed registered nurse (L.N.P.) concerning a female patient in her early 20's, who on unspecified date was vaccinated with a second 0.5 ml dose of GARDASIL (Lot # not reported) IM. The nurse said that the patient experienced systemic pruritus after being administered GARDASIL. The patient did not seek medical attention. At the time of the report the outcome of the patient was unknown. Follow-up information was received from a licensed practical nurse who stated that the 14 year old female patient with a history of pertussis per her mother and no illness at time of vaccination on 15-NOV-2010, was vaccinated IM in the right arm with the second dose of GARDASIL (lot# 666948/0886Z) at 14:40. Concomitant therapy included a dose of FLUZONE (lot# 6T3620BA) given on 02-NOV-2010, IM in the left arm at 16:15. The patient's mother reported that on 16-NOV-2010, her daughter experienced generalize body itching without rash. There was no relevant diagnostic test performed. On an unspecified date the patient recovered. The patient did not seek medical attention. No further information is available.
pt recvd vax 25OCT94 in lt deltoid during a routine physical;28OCT felt tired, had sore arm @ inj site, muscle aches & joint pain in rt hip & shoulder;APAP given blood test pos for lupus;h/o pneumonia many yrs ago;MD confirms event
08/17/2021 Dose 1 right shoulder aching had then 07/2021 COVID ; Dose 2 10/05/2021; Pain in shoulder returned both shoulder and neck stiffness, to turn head. Main thing is right hurting like stroke or negative. 10/20/2021 Returned to work. Had to go to ER due to viral infection and lung issues related to the vaccination 10/20/2021 like fogging and pass out she tested negative but had a Bradycardia and breathing issues after Dose 2. shoulder pain that will not go away. Mental Fog, and weak tired, short of breath. Sent to ER by physician and 10/27/2021 Heart and lung issues was discovered, and incurred medical leave 10/20/2021, no short term disability and on leave until March 23, 2022 may extend leave or not. Tested heart function was at 45 as last month as of yesterday 02/15/2022 40. Drops to 20 then spikes to 100. Blood pressure 163/118 then it would go back down. Bradycardia diagnosed in hospital on Losartan as of yesterday. Heart from getting weaker, unable to work or drive.
swelling; heat; bad reactions described as a firm induration of 10mm in size; This case was reported by a nurse via call center representative and described the occurrence of swelling in an unspecified number of patients who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix at an unknown dose. On an unknown date, unknown after receiving Shingrix, the patient experienced swelling, feeling hot and induration. On an unknown date, the outcome of the swelling, feeling hot and induration were unknown.   It was unknown if the reporter considered the swelling, feeling hot and induration to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not applicable for this report. The reporter stated that the several patients experienced swelling, heat and bad reactions, which she describes as a firm induration of 10mm in size. The reporter consented to follow up.
got shingles a few years after I had the shot/ suspected vaccination failure; shingles / mild case; This case was reported by a consumer via interactive digital media and described the occurrence of suspected vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, several years after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine.  Additional details were provided as follows: This case was reported by patient himself/herself. The age at vaccination was not reported. The patient stated he/she got shingles a few years after the Shingles shot. Not terribly unusual, but it also was a very mild case. The patient stated he/she been told had no reason to expect another shingles episode. The follow-up would not possible as no contact details were available. This case was considered as suspected vaccination failure as details regarding completion of primary vaccination schedule, time to onset and laboratory test confirming herpes zoster were unknown at the time of reporting.
A mother reports post vaccine within 24 hours the pt developed fever of 103F, vomiting, diarrhea, difficulty sleeping and irritability. Mother states that the child's physician does not believe symptoms are related to vaccine. Mother states her sister's child had a similar though much worse reaction. Additional information received from the physician on 03/20/2001 stated that the office was not aware of the child's adverse experience post-immunization.
Severe headache, fever over 100 for 5 days, redness and swelling at injection site (photos taken) redness became warm/hot to touch (cellulitis like), the redness moved to different parts of my arm for weeks. I did not seek medical treatment. This happened on both Moderna shots.
Low grade fever 100.0 oral-104; arthralgias & back ache then rash;
Inappropriate schedule of vaccine administered; 28 patient received expired vaccine; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (28 patient received expired vaccine) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Inappropriate schedule of vaccine administered) in a 30-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 009C21A) for COVID-19 vaccination. Previously administered products included for Product used for unknown indication: Pfizer (First dose and second dose) from 24-Mar-2021 to 14-Apr-2021. Past adverse reactions to the above products included No adverse event with Pfizer. On 10-Dec-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Dec-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (28 patient received expired vaccine). On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Inappropriate schedule of vaccine administered). On 10-Dec-2021, EXPIRED PRODUCT ADMINISTERED (28 patient received expired vaccine) had resolved. At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Inappropriate schedule of vaccine administered) had resolved. For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.No concomitant medication information was provided. 28 patient received expired vaccine. No treatment medication information was provided. This case was linked to MOD-2021-408649, MOD-2021-409288 (Patient Link).
30 minutes after pfizer vaccine dose#2 ..my left face and cheek started tingling and going numb.  Tingling sensation lasted 1 hour then went away.
pt recvd vax; devel chicken pox like rash all over body; reporter stated that pt had a "fairly mild case";pt said she still has a few more lesions
This spontaneous report as received from a registered nurse refers to a 19 year old female patient. There was no information about the patient's concurrent conditions, concomitant therapies or medical history provided. On 15-JUN-1992, the patient was vaccinated with the first dose of M-M-R II (dose, route of administration, lot # and expiration date not reported). On 11-APR-1996, she received the second dose of M-M-R II (dose, route of administration, lot # and expiration date not reported). On 20-MAY-2013, the patient was vaccinated with third dose of M-M-R II (dose, route of administration not reported) lot # H014989, expiration date 10-AUG-2014. On 05-AUG-2013, she received the fourth dose of M-M-R II (dose, route of administration not reported), lot # H014989, expiration date 10-AUG-2014. On an unknown date after the administration of all doses of M-M-R II, the patient was tested for measles antibody with a negative result. No adverse effect was reported. The outcome of measles antibody negative and the relatedness between this event and M-M-R II were not reported. Additional information has been requested.
nausea for 10-12hr w/in a few hr;used Phenergan tabs for nausea;
Client was in post vaccine monitoring area for approximately 10 minutes when she reported feeling  a little dizzy with a fast HR, states this also occurred with her 1st dose of the vaccine but quickly resolved. VS HR 104, RR 20, BP 130/80 O2 sat 99%. Client remained in monitoring area with RN staff, reported no additional symptoms, dizziness and HR symptoms resolved at 1200pm. 1210pm VS HR 90, RR 20, BP 128/72.; client denies need for any additional intervention, states she feels well enough to leave - ambulated in the waiting area with a steady gait, no dizziness returned. Client left to return to family in waiting car. At 1220pm client returned to the waiting area after using the restroom, accompanied by clinic staff reporting extreme dizziness, racing heart and palpitations. Client was unable to safely sit up in a chair and was assisted to the floor to lay down. VS: HR 123, RR24, BP 144/82 O2 sat 100%. Client continues to call out that she feels bad, the dizziness is worse and her heart is still racing with palpitations. EMS was called at 1224pm and arrived on scene at 1240pm. Client still reported dizziness and palpitations/racing heart but feels some improvement. 1240 pm client was able to sit VS: HR 90, RR 20, BP 124/70 O2 sat 99%. Client declined EMS transport or intervention at this time, her children are here and she states they will drive her home. Assisted client to stand and ambulate in the waiting area, steady gait noted and client denies any dizziness, racing heart rate or palpitations. Assisted client to the vehicle with her family, instructed to seek medical attention if symptoms return or worsen. Departed the clinic area at 1:10pm.
Booster vaccine was given 10 days after the beyond use date of 11/20/2021 Patient notified, no adverse reactions and patient has chosen not to revaccinate, stay on schedule for 2nd dose in 21 days
Similar side effects to those after first shot: headache,  mm aches, neck spasm, extremely tired, chills Rest, fluids and Tylenol
Mom reports, that night, post vax, she held her breath, turned pale, eyes went back and she became limp. She was still awake and looking around though. We were able to get her attention. The event lasted 1-2 minutes and she became normal again. She thinks child had similar episode after about 2 weeks, but didn't call for a week later and spoke with a doctor about it on 12/28/00, this time.
Left upper arm red and warm to touch near injection site. 2+ edema. Continue to monitor. Give Benadryl and Tylenol.
This spontaneous report as received from a pharmacist refers to a male patient of unknown age. On 28-AUG-2013 the patient was inadvertently vaccinated with ZOSTAVAX, vial, subcutaneous (dose, location and application site unspecified) (lot # and exp date unknown). After administration it was discovered that the patient had additional medical information, which was not disclosed prior to receiving ZOSTAVAX, which documented that he had ZOSTAVAX sometime in 2007. No adverse effects were reported. Additional information has been requested.
light-headed, dry mouth, nausea, dizziness, abnormal sensation in tongue, anxiety & hypertensive 197/96 post vaccine administration. Transported to ED, observed and symptoms resolved discharged to home. - history of anaphylaxis to shellfish and PCN, IV contrast dye allergy history
received an early third dose of Twinrix (before 6 months).; This case was reported by a physician via call center representative and described the occurrence of drug dose administration interval too short in a patient who received HAB (Twinrix) for prophylaxis.   Co-suspect products included hepatitis A and hepatitis B vaccine pre-filled syringe device (Twinrix Pre-Filled Syringe Device) injection syringe for prophylaxis.   Previously administered products included Twinrix (received 1st dose on an unknown date) and Twinrix (received 2nd dose on an unknown date).   On an unknown date, the patient received the 3rd dose of Twinrix and Twinrix Pre-Filled Syringe Device. On an unknown date, unknown after receiving Twinrix and Twinrix Pre-Filled Syringe Device, the patient experienced drug dose administration interval too short. On an unknown date, the outcome of the drug dose administration interval too short was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional details were provided as follows: The age at vaccination was not reported. The patient received an early third dose of Twinrix (Before 6 months), which led to shortening of vaccination schedule. The further information was not provided. The reporter did not consented to follow up.
A report received from a health care professional on 20Nov02, concerning a female vaccinee who inadvertently received Fluvirin SC on 20Nov02. On 20Nov02, the vaccinee was inadvertently administered Fluvirin SC. No adverse symptoms were reported. There was insufficient information to determine the reporters causality assessment.
3:00pm sore arm 4:00pm general tiredness  11:00pm full body aches, shaking, chills lasting throughout most of the night. Chills subsiding around 4:00am. Still very tired and achy throughout the next morning into the afternoon.
Patient was hospitalized, seen by cardiology with CC of palpitations. Patient was tachycardia upon arrival and diagnosed with undetermined irregular rhythm, eventually diagnosed with atrial fibrillation. He eventually spontaneously converted back to normal sinus rhythm. The documented hospitalization is attached; he had a similar experience within 10 days of the second dose of the vaccine.
1st dose in OCT 2019, 2nd dose in 2020, and 3rd dose in 2021; 1st dose in OCT 2019, 2nd dose in 2020, and 3rd dose in 2021; This case was reported by a consumer via call center representative and described the occurrence of drug dose administration interval too long in a 52-year-old male patient who received HAB (Twinrix) for prophylaxis.   Co-suspect products included hepatitis A and hepatitis B vaccine pre-filled syringe device (Twinrix Pre-Filled Syringe Device) injection syringe for prophylaxis, HAB (Twinrix) for prophylaxis and hepatitis A and hepatitis B vaccine pre-filled syringe device (Twinrix Pre-Filled Syringe Device) injection syringe for prophylaxis.   Previously administered products included Twinrix (1st dose of Twinrix suspension for injection in prefilled syringe was received in October 2019).   In November 2020, the patient received the 2nd dose of Twinrix and Twinrix Pre-Filled Syringe Device. In December 2021, the patient received the 3rd dose of Twinrix and Twinrix Pre-Filled Syringe Device. In November 2020, unknown after receiving Twinrix and Twinrix Pre-Filled Syringe Device and not applicable after receiving Twinrix and Twinrix Pre-Filled Syringe Device, the patient experienced drug dose administration interval too long. In December 2021, the patient experienced drug dose administration interval too long. On an unknown date, the outcome of the drug dose administration interval too long and drug dose administration interval too long were unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional details were reported as follows: The reporter was the patient.  The patient received his first dose of Twinrix in October 2019, second dose in November 2020 and third dose in December 2021.  The patient received 2nd and 3rd dose which led to lengthening of vaccination schedule. The patient received all 3 doses at the same pharmacy.  The reporter did not consent to followup.
Severe unrelenting migraine; nausea; vertigo; dose number:1;administration date:11Mar2021/dose number:2;administration date:28Mar2021; Severe right side abdominal pain, deep; This is a spontaneous report received from a contactable reporter(s) (Other HCP). The reporter is the patient.  A 42 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 28Mar2021 12:00 (Lot number: En6647) at the age of 43 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "Hashimoto's disease" (unspecified if ongoing); "cholecystectomy" (unspecified if ongoing), notes: Levaquin and scopolamine; "hypoglycemia" (unspecified if ongoing); "Allergies to Levaquin" (unspecified if ongoing); "Choke" (unspecified if ongoing); "gastric sleeve" (unspecified if ongoing); "Mc hernia repairs" (unspecified if ongoing); "impure metals" (unspecified if ongoing). Concomitant medication(s) included: SYNTHROID; ELETRIPTAN; ESCITALOPRAM; TRAZODONE. Past drug history included: Levaquin, reaction(s): "Drug allergy"; Scopolamine. Vaccination history included: Bnt162b2 (Dose 1, lot number: En6349 (Arm left)), administration date: 11Mar2021, for covid-19 immunisation. The following information was reported: ABDOMINAL PAIN (non-serious) with onset 22Apr2021 01:00, outcome "not recovered", described as "Severe right side abdominal pain, deep"; MIGRAINE (non-serious) with onset 29Apr2021 05:00, outcome "not recovered", described as "Severe unrelenting migraine"; NAUSEA (non-serious) with onset 29Apr2021 05:00, outcome "not recovered", described as "nausea"; VERTIGO (non-serious) with onset 29Apr2021 05:00, outcome "not recovered", described as "vertigo"; INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (non-serious) with onset 22Apr2021 01:00, outcome "unknown", described as "dose number:1;administration date:11Mar2021/dose number:2;administration date:28Mar2021". The event "severe right side abdominal pain, deep" was evaluated at the physician office visit. The events "severe unrelenting migraine", "nausea" and "vertigo" were evaluated at the physician office visit and emergency room visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of abdominal pain, migraine, nausea, vertigo.  Additional information: It was reported that Severe right side abdominal pain, deep. Not relieved by anything. Severe unrelenting migraine for 4 weeks straight and now 3 days of unrelenting vertigo and nausea. Patient received hydration, tests, mri, medicine. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination the patient was not diagnosed with COVID-19 and since the vaccination the patient has not been tested for COVID-19.  No follow-up attempts are possible. No further information is expected.
Aching muscles, joint pain, swollen glands, high fever (102F), jerky convulsions, faintness, sweating. (Dr. administered wrong vaccine, should have given MPSV4). Required hospital emergency room visit on 6/5/14.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 58-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 02Nov2022 at 13:00 as dose 4 (booster), single (Lot number: GJ5342) at the age of 58 years, in left arm for covid-19 immunisation; COVID-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Known allergies: perfume" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Jan2023, outcome "not recovered" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive. Therapeutic measures were taken as a result of drug ineffective, covid-19: the patient received Paxlovid from 23Jan2023 to 27Jan2023 for treatment of COVID-19.
patient had syncope after 25 mins ,he felt lightheaded as if he was loosing control over his body paramedics were called and came in and took him to hospital